Table 2.

Association between aspirin and NSAID use and prostate cancer risk or disease grade versus nonuse

Aspirin usersNSAID usersAspirin and NSAID users
VariableNonusersOR (95% CI)POR (95% CI)POR (95% CI)P
Overall prostate cancer risk
 Number with cancer/total753/3,169286/1,368250/1,176147/677
 UnivariableReferent0.85 (0.73–0.99)0.0360.87 (0.74–1.02)0.080.89 (0.73–1.09)0.25
 MultivariableaReferent0.81 (0.68–0.96)0.0150.92 (0.78–1.08)0.300.89 (0.72–1.10)0.28
Low-grade disease
 Number with cancer/totalb520/2,936197/1,279180/1,106103/633
 UnivariableReferent0.85 (0.71–1.01)0.070.90 (0.75–1.09)0.280.90 (0.72–1.14)0.39
 MultivariableaReferent0.83 (0.68–1.01)0.060.95 (0.79–1.15)0.620.92 (0.72–1.18)0.52
High-grade disease
 Number with cancer/totalc233/2,64989/1,17170/99644/574
 UnivariableReferent0.85 (0.66–1.10)0.220.78 (0.56–1.04)0.090.86 (0.62–1.20)0.38
 MultivariableaReferent0.77 (0.58–1.02)0.060.83 (0.62–1.10)0.190.81 (0.57–1.16)0.25
  • aAdjusted for age, race, geographic region, PSA levels, prostate volume, digital rectal examination findings, BMI, treatment arm, smoking, alcohol, statin use, hypertension, diabetes, and cardiovascular disease.

  • bNumbers reflect men included in the analysis: those with low-grade disease and those without cancer.

  • cNumbers reflect men included in the analysis: those with high-grade disease and those without cancer.